Feed Symbols: ZYNE

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment,” in the Journal of Neurodevelopmental Disorders.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome.